Julie Hallet: New NANETS Guidance on High-Grade Neuroendocrine Carcinomas
Julie Hallet, Director of Research at the Canadian Society of Surgical Oncology (CSSO), shared a post on LinkedIn about a recent article by Jennifer R. Eads et al., published in Endocrine-Related Cancer:
“Following expert statement for G3 NETs, here is some guidance for NEC (carcinoma) from NANETS
Aggressive and fast-growing cancers require different therapy than NETs.
- Loc → rare surgery for R0 with chemotherapy
- 1st-line → Platinum+etoposide, recurrence >6m → platinum vs <6m → alternate chemotherapy
- IO → not routine, for MSI/dMMR or TMB-high”
Title: Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Journal: Endocrine-Related Cancer
Authors: Jennifer R. Eads, Thorvardur R. Halfdanarson, Tim Asmis, Andrew M. Bellizzi, Emily K. Bergsland, Arvind Dasari, Ghassan El-Haddad, Michael Frumovitz, Joshua Meyer, Erik Mittra, Sten Myrehaug, Eric Nakakura, Nitya Raj, Heloisa P. Soares, Brian Untch, Namrata Vijayvergia, Jennifer A. Chan
More posts featuring Julie Hallet on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023